Availability
0
Your Basket is Empty
BB160379

BLU 554 - Bio-X

A potent and selective covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4). This receptor tyrosine kinase activates an oncogenic driver in hepatocellular carcinoma, the fibroblast growth factor 19 (FGF19). The FGFR4 inhibitor is therefore a promising candidate for the treatment of advanced liver cancer.

Technical Data

CAS No: 1707289-21-1
Synonyms: N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide
Product Code: BB160379
Chemical Formula: C24H24Cl2N4O4
Molecular Weight: 503.38

References


  • Blueprint Medicines Corporation (2017). Discovery and development of BLU-554: a potent, highly selective covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) in development for the targeted treatment of advanced hepatocellular carcinoma (HCC) patients with amplified and overexpressed FGF19. Abstract for presentation at Amer Chem Soc Meeting.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

BLU 554 - Bio-X

CAS No:
1707289-21-1
Synonyms:
N-((3S,4S)-3-((6-(2,6-Dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl)amino)tetrahydro-2H-pyran-4-yl)acrylamide
Chemical Formula:
Molecular Weight:
503.38
Product Structure
References:
1. Blueprint Medicines Corporation (2017). Discovery and development of BLU-554: a potent, highly selective covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) in development for the targeted treatment of advanced hepatocellular carcinoma (HCC) patients with amplified and overexpressed FGF19. Abstract for presentation at Amer Chem Soc Meeting.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...